Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow STANDARD BIOTOOLS INC.

Get SEC filing alerts via email and in your feed for STANDARD BIOTOOLS INC.

LAB

STANDARD BIOTOOLS INC.

About STANDARD BIOTOOLS INC.

Standard BioTools Inc. develops and commercializes advanced life science tools in proteomics and genomics, including instruments, consumables, and services for biomedical research, drug discovery, and clinical applications. Its platforms—SomaScan, CyTOF, Hyperion, and Biomark—enable high-throughput, precise molecular analysis across diverse therapeutic areas. The company serves research institutions, biopharma, and clinical labs worldwide, leveraging proprietary technologies and strategic acquisitions to accelerate biological insights and health innovations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from STANDARD BIOTOOLS INC.

1
1
STANDARD BIOTOOLS INC. Standard BioTools Reports $21.1 Million Revenue and $127.1 Million Net Income in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
STANDARD BIOTOOLS INC. Standard BioTools Reports $85.3 Million Revenue Decline and Restructuring Efforts for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
STANDARD BIOTOOLS INC. Standard BioTools Inc. Reports Decline in Revenue and Increased Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
STANDARD BIOTOOLS INC. Standard BioTools Reports Q2 2025 Revenue Decline, Announces Illumina Acquisition

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
STANDARD BIOTOOLS INC. Standard BioTools Inc. Reports 10% Revenue Decline and $26M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
STANDARD BIOTOOLS INC. Standard BioTools Inc. Reports 64% Revenue Growth to $174.4 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
STANDARD BIOTOOLS INC. Standard BioTools Reports 77% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments